Skip left side navigation and go to content

Life After Linkage RFA –HL-12-007
Frequently Asked Questions

  1. When is the application due?
    The application is due June 15, 2011 at 5:00 p.m. local time of applicant organization.

  2. Letter of Intent – when is it due and is it required?
    The letter of intent is due May 16, 2011. The letter of intent is not required, but is encouraged. It allows the Institute staff to assess responsiveness, estimate the potential review workload and plan the review. Instructions for the letter and where to send it are found in Section IV.2 of the RFA.

  3. Is this RFA eligible to be submitted as a multiple PI application?
    Yes

  4. Are Foreign investigators/institutions eligible to submit applications to this RFA?
    Yes

  5. Can I receive consideration as an Early Stage Investigator (ESI)?
    No, the ESI policy does not apply to Requests for Applications (RFA).

  6. This is my first application. If I receive an award, can I be considered an ESI on subsequent R01s?
    No, this award would negate your status as an ESI on subsequent R01 applications.

  7. How many applications will be funded?
    We anticipate funding approximately 5-7 applicatons.

  8. Are these awards renewable?
    No, subsequent applications for funding would be submitted as an investigator-initiated R01.

  9. Does this RFA follow the same pay line as R01 awards?
    No, awards under this RFA will receive a priority score and will be funded based on ranking of applications reviewed under this RFA and programmatic balance.

  10. For the purpose of this RFA, how are complex disorders distinguished from Mendelian disorders?
    This RFA will support studies of complex disorders. Complex disorders will be influenced by multiple genetic variants and environmental factors. A given genetic variant should segregate in more than one family. The disorder should exhibit a clear public health impact. This includes complex phenotypes with evidence of heritability and transmission in families.

  11. Will phenotypes that are not traditional NHLBI traits, such as obesity, kidney disease, insulin resistance, be considered responsive to this RFA?
    Phenotypes that are responsive to this RFA must be risk factors or clinical phenotypes related to heart, lung, blood or sleep disorders. For example, studies addressing cancer are not responsive to this RFA even if the metastatic tissue is heart, lung or blood related.

  12. For the purpose of this RFA, what is the definition of a family?
    A family is defined as two first degree or more related individuals. Twins and sib pairs will be regarded as families. The choice of family structure and size should be justified in terms of the scientific question and statistical power. Some questions may be addressed in sib pars, others may require multigeneration pedigrees.

  13. How much preexisting genotype and phenotype data are needed to be responsive to this RFA?
    Genome wide genotyping (microsatellite, metabochip, GWAS SNPs, etc.) should be available for all participants in the study. The basic phenotypes of interest should be already measured and available for all participants in the study. This RFA will support additional focused genotyping or sequencing (targeted, exome or whole genome) and well justified, limited in depth phenotyping. A limited number of additional family members may be recruited if justified for focused genotyping or sequencing and in depth phenotyping. This RFA will not support recruitment of new families or de novo genotyping and phenotyping in the entire sample.



Last Updated April 2011




Skip footer links and go to content
Twitter iconTwitterExternal link Disclaimer         Facebook iconFacebookimage of external link icon         YouTube iconYouTubeimage of external link icon         Google+ iconGoogle+image of external link icon